Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:40:50.748Z.
Consensus retrieved: 2026-10-06T09:50:06.460Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:40:50.748Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 953d1456faf84e3d3f88a5480ffc5766df2e412b5fda6c1fb2fa7c75cf2e613b
Forward PE Ratio (N/A) = Dated Quote Price ($2.02) / Consensus Forward EPS ($-1.36)
FORWARD PE RATIO
N/A
Cabaletta Bio, Inc.
Market Cap
$329.37M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cabaletta Bio, Inc. (CABA) | $329.37M | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A |
| CapsoVision, Inc. (CV)vs › | $324.76M | N/A |
| Avita Medical Inc. (RCEL)vs › | $322.71M | N/A |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 184.21 |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A |
| Agenus Inc. (AGEN)vs › | $311.90M | 28.00 |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.02, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.36 | $-1.46 – $-1.17 | 5 | n/m |
| 2027-12-31 | $-1.20 | $-1.37 – $-1.08 | 4 | n/m |
| 2028-12-31 | $-0.99 | $-1.40 – $-0.51 | 7 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
